215 related articles for article (PubMed ID: 16506600)
1. [Isolated lymphadenopathy as the first presentation of systemic mastocytosis--description of two cases].
Kinkor Z; Síma R; Skálová A; Boudová L; Peková S; Dvoráková D; Dĕdic K; Kracík M; Janousek M; Michal M
Cesk Patol; 2006 Jan; 42(1):34-8. PubMed ID: 16506600
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.
Ustun C; Savage NM; Gotlib J; Bhalla K; Manaloor E; George TI
Am J Hematol; 2012 Feb; 87(2):191-3. PubMed ID: 22081475
[No Abstract] [Full Text] [Related]
3. A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study.
Wang X; Zhang L; Zhou D; Cai H; Wang X; Jiang X
Medicine (Baltimore); 2020 Dec; 99(50):e21948. PubMed ID: 33327223
[TBL] [Abstract][Full Text] [Related]
4. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
5. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
Tefferi A; Lasho TL; Brockman SR; Elliott MA; Dispenzieri A; Pardanani A
Haematologica; 2004 Jul; 89(7):871-3. PubMed ID: 15257945
[TBL] [Abstract][Full Text] [Related]
6. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
7. [Clinical observations in cutan mastocytosis].
Mihalik N; Hidvégi B; Hársing J; Várkonyi J; Csomor J; Kovalszky I; Marschalkó M; Kárpáti S
Orv Hetil; 2013 Sep; 154(37):1469-75. PubMed ID: 24016753
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
9. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
[TBL] [Abstract][Full Text] [Related]
10. [Systemic mastocytosis. Classification, symptoms, therapy].
Kraemer DM; Grunewald SM; Kolb-Mäurer A
Med Klin (Munich); 2004 Mar; 99(3):131-6. PubMed ID: 15024485
[TBL] [Abstract][Full Text] [Related]
11. Cytology of systemic mastocytosis.
Bain BJ; Marks AJ
Am J Hematol; 2009 Dec; 84(12):842. PubMed ID: 19787646
[No Abstract] [Full Text] [Related]
12. Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
Falleti J; Borgia L; Lalinga AV; De Cecio R; Natella V; Patitucci G; Vita G
Pathol Res Pract; 2012 Nov; 208(11):683-6. PubMed ID: 22963840
[TBL] [Abstract][Full Text] [Related]
13. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
14. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
15. [Case of systemic mastocytosis with hemophagocytic syndrome].
Watanabe A; Takahashi N; Yoshioka T; Miura I; Sawada K
Nihon Naika Gakkai Zasshi; 2003 May; 92(5):874-6. PubMed ID: 12808914
[No Abstract] [Full Text] [Related]
16. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.
Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP
J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565
[TBL] [Abstract][Full Text] [Related]
17. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
18. [IgE mediated anaphylaxis in a patient with systemic mastocytosis].
Escande H; Bennani I; Bulai Livideanu C; Uthurriague C; Paul C; Nougué J
Ann Dermatol Venereol; 2013 Oct; 140(10):641-4. PubMed ID: 24090896
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis.
Ozdemir D; Dagdelen S; Erbas T
Am J Med Sci; 2011 Nov; 342(5):409-15. PubMed ID: 21629042
[TBL] [Abstract][Full Text] [Related]
20. Clinical, genetic, and therapeutic insights into systemic mast cell disease.
Tefferi A; Pardanani A
Curr Opin Hematol; 2004 Jan; 11(1):58-64. PubMed ID: 14676628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]